{"id":477704,"date":"2020-04-03T13:02:01","date_gmt":"2020-04-03T13:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477704"},"modified":"2020-04-03T13:02:01","modified_gmt":"2020-04-03T13:02:01","slug":"focal-segmental-glomerulosclerosis-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/focal-segmental-glomerulosclerosis-market-insights-epidemiology-and-market-forecast2030_477704.html","title":{"rendered":"Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast-2030"},"content":{"rendered":"
\"Focal<\/a><\/div>\n

 <\/p>\n

DelveInsight has launched a new report on Focal Segmental Glomerulosclerosis Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Focal Segmental Glomerulosclerosis (FSGS) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis (FSGS), historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis (FSGS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Focal Segmental Glomerulosclerosis (FSGS) market report provides current treatment practices, emerging drugs, Focal Segmental Glomerulosclerosis (FSGS) market share of the individual therapies, current and forecasted Focal Segmental Glomerulosclerosis (FSGS) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Focal Segmental Glomerulosclerosis (FSGS) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Focal segmental glomerulosclerosis (FSGS) is a well-defined histologic pattern of injury characterized by sclerosis, hyalinosis, foam-cell infiltration, vacuolization of podocytes, and podocyte precursor proliferation between glomeruli tuft and Bowman’s capsule. It is “focal” in that only some glomeruli are affected and “segmental” where only a portion of the affected glomerulus is sclerosed. FSGS may be found either as primary or secondary forms. Primary FSGS sometimes has no identifiable cause or known etiology and linked to genetic mutations in podocyte-specific proteins, while secondary FSGS might include familial\/genetic forms, virus-associated forms, drug-induced forms, and forms mediated by adaptive structural-functional response. The clinical features of FSGS include peripheral edema, marked proteinuria, hypertension, hypoalbuminemia, hyperlipidemia, and progressive loss of renal function. The pathogenesis of FSGS is very complex, mostly podocyte injury and parietal epithelial cells lining Bowman’s capsule play a central role in the disease progression. FSGS is classified as collapsing, tip, cellular, perihilar, and not otherwise specified variants according to the location and character of the sclerotic lesion (Columbia Classification).<\/div>\n
\"\"<\/div>\n
 <\/div>\n
Request for :- FSGS free sample page<\/a><\/div>\n
 <\/div>\n
Epidemiology <\/strong><\/em><\/div>\n
The Focal Segmental Glomerulosclerosis (FSGS) epidemiology division provide insights about historical and current Focal Segmental Glomerulosclerosis (FSGS)<\/span> <\/span>patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.<\/span><\/div>\n
 <\/div>\n
Report Key facts:- <\/strong><\/div>\n
 <\/div>\n
1. <\/strong><\/strong>Age plays important role in the prevalence of FSGS. As per DelveInsight estimates, there were 4,306 cases of children with FSGS, while adults contribute 8,613 cases of FSGS in 2017 for Germany.<\/div>\n
 <\/div>\n
2. In 2017, there were 45,852 prevalent cases of FSGS in males and 34,731 cases in females and as per analyst assessments, the overall cases of FSGS in both the genders is subjected to increase in the coming years in 7MM.<\/div>\n
 <\/div>\n
3. Among the European 5 countries, the Germany had highest prevalent population of FSGS with 21,532 cases, followed by France. On the other hand, Spain had the lowest prevalent population of Focal Segmental Glomerulosclerosis.<\/div>\n
 <\/div>\n
“According to DelveInsight’s analysis, Male cases of FSGS are more prominent in comparison to Female” <\/strong><\/em><\/div>\n
 <\/div>\n
Key companies are working on FSGS are given below:- <\/strong><\/em><\/div>\n
 <\/div>\n
1. Retrophin Pharma Co.<\/em><\/div>\n
2. Dimerix Pharma Co. <\/em><\/div>\n
3. Aurinia Pharmaceutical Co. <\/em><\/div>\n
 <\/div>\n
Name of drugs covered that are given below:-<\/em><\/strong><\/div>\n
 <\/div>\n
1. <\/em><\/strong>Sparsentan<\/em><\/div>\n
2. DMX 200<\/em><\/div>\n
3. Voclosporin<\/span><\/em><\/div>\n
 <\/div>\n
Table of contents<\/em><\/a><\/div>\n
 <\/div>\n
\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Focal Segmental Glomerulosclerosis (FSGS)<\/span><\/p>\n

3. Competitive Intelligence Analysis for Focal Segmental Glomerulosclerosis (FSGS)<\/span><\/p>\n

4. Focal Segmental Glomerulosclerosis (FSGS): Market Overview at a Glance<\/span><\/p>\n

4.1. Focal Segmental Glomerulosclerosis (FSGS) Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Focal Segmental Glomerulosclerosis (FSGS) Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Focal Segmental Glomerulosclerosis (FSGS): Disease Background and Overview<\/span><\/p>\n

6. Patient Journey<\/p>\n

7. Focal Segmental Glomerulosclerosis (FSGS) Epidemiology and Patient Population<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

8.1. Focal Segmental Glomerulosclerosis (FSGS) Treatment and Management<\/span><\/p>\n

8.2. Focal Segmental Glomerulosclerosis (FSGS) Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Focal Segmental Glomerulosclerosis (FSGS) Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

12. Emerging Therapies<\/p>\n

13. Focal Segmental Glomerulosclerosis (FSGS): Seven Major Market Analysis<\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Focal Segmental Glomerulosclerosis (FSGS) Market Size in 7MM<\/span><\/p>\n

13.3. Focal Segmental Glomerulosclerosis (FSGS) Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

16. Access and Reimbursement Overview of Focal Segmental Glomerulosclerosis (FSGS)<\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About DelveInsight<\/a><\/p>\n

Why should you buy this report?<\/strong><\/em><\/p>\n